Last reviewed · How we verify

Qinggongshoutao Bolus

Dongzhimen Hospital, Beijing · FDA-approved active Small molecule Quality 2/100

Qinggongshoutao Bolus is a Small molecule drug developed by Dongzhimen Hospital, Beijing. It is currently FDA-approved. Also known as: Ginkgo biloba also named Egb761 or Ginaton.

At a glance

Generic nameQinggongshoutao Bolus
Also known asGinkgo biloba also named Egb761 or Ginaton
SponsorDongzhimen Hospital, Beijing
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Qinggongshoutao Bolus

What is Qinggongshoutao Bolus?

Qinggongshoutao Bolus is a Small molecule drug developed by Dongzhimen Hospital, Beijing.

Who makes Qinggongshoutao Bolus?

Qinggongshoutao Bolus is developed and marketed by Dongzhimen Hospital, Beijing (see full Dongzhimen Hospital, Beijing pipeline at /company/dongzhimen-hospital-beijing).

Is Qinggongshoutao Bolus also known as anything else?

Qinggongshoutao Bolus is also known as Ginkgo biloba also named Egb761 or Ginaton.

What development phase is Qinggongshoutao Bolus in?

Qinggongshoutao Bolus is FDA-approved (marketed).

Related